References
- Davis GL, Balart LA, Schiff ER, Lindsay K, Bodenheimer HC, Perillo RP, et al. Treatment of chronic hepatitis C with recombinant interferon alpha: a multicenter randomized, controlled trial. N Engl J Med 1989;321:1501–6.
- Tine F, Magrin S, Craxi A, Pagliaro L. Interferon for non-A, non-B chronic hepatitis. A metaanalysis of randomized clinical trials. J Hepatology 1991;13:192–9.
- Poynard T, Leroy V, Cohard M, Thevenot T, Mathurin P, Opolon P, et al. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration. Hepatology 1996;24:778–89.
- Hoofnagle JH, Bisceglie AM. The treatment of chronic viral hepatitis. N Engl J Med 1997;336:347–56.
- Reichard O, Andersson J, Schwarz R, Weiland O. Ribavirin treatment for chronic hepatitis C. Lancet 1991;337:1058–61.
- Brillanti S, Garson J, Foli M, Whitby K, Deaville R, Masci C, et al. A pilot study of combination therapy with ribavirin plus interferon alfa for interferon alfa- resistant chronic hepatitis C. Gastroenterology 1994;107:812–7.
- Kakumu S, Yoshioka K, Wakita T, Ishikawa T, Takayanagi M, Higashi Y. A pilot study of ribavirin and interferon beta for the treatment of chronic hepatitis C. Gastroenterology 1993;105:507–12.
- Schalm S, Hansen B, Chemello L, Bellobuoni A, Brouwer JT, Weiland O, et al. Ribavirin enhances the efficacy but not the adverse advents of interferon in chronic hepatitis C: a metaanalysis of individual patient data from European centers. J Hepatol 1997;26:961–6.
- Chemello L, Cavaletto L, Bernardinello E, Silvestri E, Benvegnu L, Pontisso P, et al. Response to ribavirin, to interferon and to a combination of both in patients with chronic hepatitis and its relation to HCV genotypes. J Hepatol 1994; 21:Abstract S17.
- Schwarz R, Ando Y, S0nnerborg A, Weiland O. Combination therapy treatment with interferon alfa-2b and ribavirin for chronic hepatitis C in patients who failed to achieve sustained response to interferon alone: Swedish experiment. J Hepatol 1995;23 Suppl 2:17–21.
- Reichard O, Norkrans G, Fryden A, Braconier J-H, S0nnenberg A, Weiland O, et al. Randomized, double-blind, placebocontrolled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. Lancet 1998;351: 83–7.
- Bell H, Hellum K, Harthug S, Mæland A, Ritland S, Myrvang B, et al. Genotype, viral load and age as independent predictors of treatment outcome of interferon-alpha2a treatment in patients with chronic hepatitis C. Scand J Infect Dis 1997;29: 17–22.
- Young KKY, Resnick RM, Myers TW. Detection of hepatitis C virus RNA by combined reverse transcription-polymerase chain reaction assay. J Clin Microbiol 1993;31:82–91.
- Bhattacherjee V, Prescott LE, Pike I, Rodgers B, Bell H, El- Zaidi AR, et al. Use of NS-4 peptides to identify type-specific antibody to hepatitis C virus genotypes 1,2,3,4,5 and 6. J Gen Virol 1995;76: 1737–48.
- Reichard O, Schvarcz R, Weiland O. Therapy of hepatitis C: alpha interferon and ribavirin. Hepatology 1997;26 Suppl 1:108 S–11S.
- Alberti A, Chemello L, Noventa F, Cavalletto L, De Salvo GL. Therapy of hepatitis C. Re-treatment with alpha interferon. Hepatology 1997;26 Suppl 1:137S–42S.
- Davis GL, Esteban-Mur R, Rustgi V, Hoefs J, Gordon SC, Trepo C, et al. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. N Engl J Med 1998;339:1493–9.
- Hawkins A, Davidson F, Simmonds P. Comparison of plasma virus load among individuals infected with hepatitis C virus (HCV) genotypes 1,2, and 3 by the Quantiplex HCV RNA assay versions 1 and 2, Roche Monitor assay, and an in-house limiting dilution method. J Clin Microbiol 1997;35: 187–92.